Quadrature Capital’s Tonix Pharmaceuticals TNXP Stock Holding History

Quadrature Capital’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,410	Closed	-$239K	–	2054
2026 Q1	$239K	Buy	+17,410	New	+$268K	﹤0.01%	1059

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital's TNXP Position: Q2 2026 in Review

Quadrature Capital sold out of Tonix Pharmaceuticals (TNXP) in Q2 2026, closing a stake of 17,410 shares — an estimated $239K sold.

Quadrature Capital first reported a position in TNXP in Q1 2026 and held it in 1 quarter. The position peaked at $239K in Q1 2026. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

Quadrature Capital reported no remaining Tonix Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 17,410 Tonix Pharmaceuticals shares in Q2 2026, an estimated $239K.
Quadrature Capital first reported a position in Tonix Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Quadrature Capital's Tonix Pharmaceuticals position peaked at $239K in Q1 2026.
103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.